Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. (Q47959338)
Jump to navigation
Jump to search
scientific article published on 14 September 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. |
scientific article published on 14 September 2017 |
Statements
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial (English)
Marc S Sabatine
Lawrence A Leiter
Stephen D Wiviott
Prakash Deedwania
Julia F Kuder
Ioanna Gouni-Berthold
Basil S Lewis
Yehuda Handelsman
Armando Lira Pineda
Narimon Honarpour
Anthony C Keech
Peter S Sever
Terje R Pedersen
15 September 2017